Patent: 8,852,608
✉ Email this page to a colleague
Summary for Patent: 8,852,608
Title: | Antibodies against and methods for producing vaccines for respiratory syncytial virus |
Abstract: | The present invention relates to novel respiratory syncytial virus (RSV) F peptides and compositions comprising them. The present invention also relates to methods of evaluating anti-RSV antibody binding to F peptides. The present invention also relates to antibodies that immunospecifically bind to an F peptide of the present invention. The invention further provides methods and protocols for the administration of F peptides and/or antibodies that immunospecifically bind to F peptides for the prevention, neutralization, treatment of RSV infection. Additionally, the methods of the invention may be useful for the treatment, prevention and the amelioration of symptoms associated with RSV infection. |
Inventor(s): | McAuliffe; Josephine (Gaithersburg, MD), Palmer-Hill; Frances (Gaithersburg, MD), Zhu; Qing (Gaithersburg, MD), Suzich; Joann (Gaithersburg, MD) |
Assignee: | MedImmune, LLC (Gaithersburg, MD) |
Application Number: | 13/147,051 |
Patent Claims: | see list of patent claims |
Details for Patent 8,852,608
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Swedish Orphan Biovitrum Ab (publ) | SYNAGIS | palivizumab | For Injection | 103770 | 06/19/1998 | ⤷ Try a Trial | 2029-02-02 |
Swedish Orphan Biovitrum Ab (publ) | SYNAGIS | palivizumab | Injection | 103770 | 07/23/2004 | ⤷ Try a Trial | 2029-02-02 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |